<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03660943</url>
  </required_header>
  <id_info>
    <org_study_id>CNTX-4975i-OA-304</org_study_id>
    <nct_id>NCT03660943</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Test Efficacy and Safety of Repeat Doses of CNTX-4975-05 in Patients With Osteoarthritis Knee Pain</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, 2-Injection, 52-Week Study to Evaluate the Efficacy and Safety of Intra-articular Injections of CNTX-4975-05 in Subjects With Chronic, Moderate-to-severe Osteoarthritis Knee Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centrexion Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centrexion Therapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, 2-injection, 52-week study to
      evaluate the efficacy and safety of intra-articular injections of CNTX-4975-05 in subjects
      with chronic, moderate-to-severe osteoarthritis knee pain.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 9, 2018</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analgesic Efficacy using Numeric Pain Rating Scale (NPRS)</measure>
    <time_frame>Baseline at Week 12</time_frame>
    <description>Evaluation of the analgesic efficacy on pain with walking of CNTX-4975-05, compared to placebo, when administered as the first intra-articular (IA) injection into the index knee using NPRS (0-10; 0 = no pain, 10 = worst pain ever).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analgesic Efficacy using Numeric Pain Rating Scale (NPRS)</measure>
    <time_frame>Baseline through 52 weeks</time_frame>
    <description>Evaluation of the analgesic efficacy of CNTX-4975-05 using NPRS (0-10; 0 = no pain, 10 = worst pain ever).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stiffness and Function using WOMAC</measure>
    <time_frame>Baseline through 52 weeks</time_frame>
    <description>Evaluation of pain, stiffness and function as assessed by WOMAC A, B, and C (11-box Numerical Rating Scale).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Improvement in Osteoarthritis (OA) Pain using Patient Global Impression of Change (PGIC)</measure>
    <time_frame>Baseline through 52 weeks</time_frame>
    <description>Evaluation of OA pain as assessed by PGIC (1-7; 1 = very much improved, 7 = very much worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life and Effect on Sleep using EQ-5D-5L Questionnaire</measure>
    <time_frame>Baseline through 52 weeks</time_frame>
    <description>Evaluation of the quality of life as assessed by EQ-5D-5L Questionnaire consisting of daily functioning (1-5; 1 = no/none, 5 = extremely) and daily health (0-100; 0 = worst, 100 = best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Analgesic Efficacy using NPRS</measure>
    <time_frame>Baseline through 52 weeks</time_frame>
    <description>Evaluation of the duration of analgesic efficacy of CNTX-4975-05 as measured by the time from Day 1 (Baseline) to the return of Baseline (NPRS pain with walking) pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders</measure>
    <time_frame>Baseline through 52 weeks</time_frame>
    <description>Evaluation of the percentage of responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Second Dose: Analgesic Efficacy using Numeric Pain Rating Scale (NPRS)</measure>
    <time_frame>Week 38 and through Week 52</time_frame>
    <description>Evaluation of the analgesic efficacy of CNTX-4975-05 using NPRS (0-10; 0 = no pain, 10 = worst pain ever).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Second Dose: Percentage of Responders</measure>
    <time_frame>Week 38 and through Week 52</time_frame>
    <description>Evaluation of the percentage of responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Second Dose: Pain, Stiffness and Function using WOMAC</measure>
    <time_frame>Week 38 and through Week 52</time_frame>
    <description>Evaluation of stiffness and function as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) A, B, and C subscales (11-box Numerical Rating Scale 0-11; 0 = no pain/stiffness/difficulty, 10= extreme).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Second Dose: Global Improvement in Osteoarthritis (OA) Pain using Patient Global Impression of Change (PGIC)</measure>
    <time_frame>Week 38 and through Week 52</time_frame>
    <description>Evaluation of osteoarthritis pain and overall improvement as assessed by Patient Global Impression of Change (PGIC) (1-7; 1 = very much improved, 7 = very much worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life and Effect on Sleep using EQ-5D-5L Questionnaire</measure>
    <time_frame>Week 38 and through Week 52</time_frame>
    <description>Evaluation of the quality of life as assessed by EQ-5D-5L Questionnaire consisting of daily functioning (1-5; 1 = no/none, 5 = extremely) and daily health (0-100; 0 = worst, 100 = best).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">332</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intra-articular Placebo Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CNTX-4975-05 (trans-capsaicin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-articular 1.0 mg CNTX-4975-05 Injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Receiving Placebo Injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CNTX-4975-05 (trans-capsaicin)</intervention_name>
    <description>Receiving CNTX-4975-05 Injection</description>
    <arm_group_label>CNTX-4975-05 (trans-capsaicin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Male or female subjects between 40 and 95 years of age (inclusive) at the time of the
             Screening Visit with the ability to comply with answering the electronic diary using
             the study- provided tablet computers.

          -  Confirmation of osteoarthritis (OA) of the knee.

          -  Confirmation of the OA of the index knee.

          -  Moderate to severe pain in the index knee associated with OA must be stable for a
             minimum of 6 months prior to Screening, as assessed by the investigator.

          -  Body Mass Index (BMI) ≤45 kg/m^2

          -  Must have failed 2 or more prior therapies.

        Exclusion Criteria:

          -  Joint replacement surgery of the index knee at any time, or open surgery of the index
             knee in the past 24 months.

          -  Prior arthroscopic surgery of the index knee within 6 months of Screening.

          -  Any painful conditions of the index knee due to joint disease other than the OA.

          -  Periarticular pain from any cause.

          -  Other chronic pain anywhere in the body that requires the use of analgesic
             medications.

          -  Instability of the index knee.

          -  Misalignment (&gt;10 degrees varus or valgus) of the index knee on standing.

          -  Documented history of neuropathic arthropathy or finding of bony fragmentation in the
             index knee with imaging.

          -  Physical/ occupational/ chiropractic therapy for the lower extremities or acupuncture
             for the lower extremities within 30 days of Screening, or need for such therapy during
             the study.

          -  Plans to have surgery, other invasive procedures, or IA injections while participating
             in the study.

          -  Has used topical capsaicin on the index knee within 90 days of Screening.

          -  Current use of opioids for any condition other than for OA of the index knee.

          -  Corticosteroid injection into the index knee within 90 days of Screening.

          -  Received IA viscosupplementation (eg, Synvisc®, Hyalgan®) within 90 days of Screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randall Stevens, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centrexion Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Holland Center for Family Health</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GB Family Care</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med Center Medical Clinic</name>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <zip>95608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TriWest Research Associates</name>
      <address>
        <city>El Cajon</city>
        <state>California</state>
        <zip>92020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Care and Research Center, Inc. (ACRC Studies)</name>
      <address>
        <city>Poway</city>
        <state>California</state>
        <zip>92064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chase Medical Research, LLC</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Marcus Research Clinic, Inc.</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Panamerican Health Center, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Well Pharma Medical Research, Corp</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Research &amp; Medical Center LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Journey Research, Inc.</name>
      <address>
        <city>Oldsmar</city>
        <state>Florida</state>
        <zip>34677</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M&amp;M Clinical Trials Sunrise</name>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <zip>33351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Conquest Research</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Better Health Clinical Research, Inc.</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healthcare Research Network, LLC</name>
      <address>
        <city>Flossmoor</city>
        <state>Illinois</state>
        <zip>60422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affinity Clinical Research Institute</name>
      <address>
        <city>Oak Brook</city>
        <state>Illinois</state>
        <zip>60523</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DelRicht Research</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Rheumatology and Bone Research</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BTC of New Bedford, LLC</name>
      <address>
        <city>New Bedford</city>
        <state>Massachusetts</state>
        <zip>02740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healthcare Research Network</name>
      <address>
        <city>Hazelwood</city>
        <state>Missouri</state>
        <zip>63042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Robert P. Kaplan, DO</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drug Trials America</name>
      <address>
        <city>Hartsdale</city>
        <state>New York</state>
        <zip>10530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lillestol Research LLC</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center at Arcis Healthcare, LLC dba Lowcountry Orthopaedics &amp; Sports Medicine</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Medical, PC</name>
      <address>
        <city>New Tazewell</city>
        <state>Tennessee</state>
        <zip>37825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Surgical Hospital</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCT-Stone Oak, LLC dba Discovery Clinical Trials</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Medical, Inc.</name>
      <address>
        <city>Danville</city>
        <state>Virginia</state>
        <zip>24541</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 27, 2018</study_first_submitted>
  <study_first_submitted_qc>September 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2018</study_first_posted>
  <last_update_submitted>August 1, 2019</last_update_submitted>
  <last_update_submitted_qc>August 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Knee Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capsaicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

